206 related articles for article (PubMed ID: 34752581)
1. Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.
Stevens DL; Hix M; Gildon BL
J Pharm Technol; 2021 Aug; 37(4):209-215. PubMed ID: 34752581
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar's healthcare perspective.
Adel AM; Abushanab D; Al-Badriyeh D; Hamad A; Alshurafa A; Yassin MA
SAGE Open Med; 2024; 12():20503121231224551. PubMed ID: 38711465
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
[TBL] [Abstract][Full Text] [Related]
4. Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report.
Alshurafa A; Yassin MA
Front Med (Lausanne); 2022; 9():1048571. PubMed ID: 36523780
[TBL] [Abstract][Full Text] [Related]
5. The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease.
Delgado J; Voltz C; Stain M; Lapveteläinen T; Urach S; Lähteenvuo J; Penttilä K; Gisselbrecht C; Enzmann H; Pignatti F
Hemasphere; 2021 Jul; 5(7):e604. PubMed ID: 34235401
[TBL] [Abstract][Full Text] [Related]
6. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Ataga KI; Kutlar A; Kanter J; Liles D; Cancado R; Friedrisch J; Guthrie TH; Knight-Madden J; Alvarez OA; Gordeuk VR; Gualandro S; Colella MP; Smith WR; Rollins SA; Stocker JW; Rother RP
N Engl J Med; 2017 Feb; 376(5):429-439. PubMed ID: 27959701
[TBL] [Abstract][Full Text] [Related]
7. Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease.
Weaver SB; Rungkitwattanakul D; Singh D
J Pharm Pract; 2023 Feb; 36(1):139-148. PubMed ID: 34151636
[TBL] [Abstract][Full Text] [Related]
8. Crizanlizumab: First Approval.
Blair HA
Drugs; 2020 Jan; 80(1):79-84. PubMed ID: 31933169
[TBL] [Abstract][Full Text] [Related]
9. P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab.
Karki NR; Kutlar A
J Pain Res; 2021; 14():849-856. PubMed ID: 33833562
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease.
Sy SKB; Tanaka C; Grosch K
Clin Pharmacokinet; 2023 Feb; 62(2):249-266. PubMed ID: 36529836
[TBL] [Abstract][Full Text] [Related]
11. Crizanlizumab in sickle cell disease.
Kaur K; Kennedy K; Liles D
Pain Manag; 2023 Oct; ():. PubMed ID: 37850353
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease.
Kanter J; Brown RC; Norris C; Nair SM; Kutlar A; Manwani D; Shah N; Tanaka C; Bodla S; Sanchez-Olle G; Albers U; Liles D
Blood Adv; 2023 Mar; 7(6):943-952. PubMed ID: 36355805
[TBL] [Abstract][Full Text] [Related]
13. Potential efficacy of crizanlizumab in treating priapism in sickle cell disease: A case report.
Abdulgayoom M; Afana MS; Alshurafa A; Yassin MA
Clin Case Rep; 2024 May; 12(5):e8585. PubMed ID: 38736574
[TBL] [Abstract][Full Text] [Related]
14. Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.
Kanter J; Ataga KI; Bhasin N; Guarino S; Kutlar A; Lanzkron S; Manwani D; McGann P; Stowell SR; Tubman VN; Yermilov I; Campos C; Broder MS
Ann Hematol; 2024 Jun; 103(6):1909-1917. PubMed ID: 38642304
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine.
Migotsky M; Beestrum M; Badawy SM
Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287444
[TBL] [Abstract][Full Text] [Related]
16. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S
Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735
[TBL] [Abstract][Full Text] [Related]
17. Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report.
Afana MS; Abu-Tineh M; Alshurafa A; Yasin AK; Ahmed K; Abdulgayoom M; Yassin MA
Hematology; 2023 Dec; 28(1):2229115. PubMed ID: 37519115
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience of patients with sickle cell disease treated with crizanlizumab.
Chan KH; Buddharaju R; Idowu M
J Investig Med; 2024 Feb; 72(2):242-247. PubMed ID: 38073007
[TBL] [Abstract][Full Text] [Related]
19. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
Kutlar A; Kanter J; Liles DK; Alvarez OA; Cançado RD; Friedrisch JR; Knight-Madden JM; Bruederle A; Shi M; Zhu Z; Ataga KI
Am J Hematol; 2019 Jan; 94(1):55-61. PubMed ID: 30295335
[TBL] [Abstract][Full Text] [Related]
20. Emerging Therapies for the Management of Pain and Vaso-Occlusive Crises in Patients With Sickle Cell Disease: A Systematic Review of Randomized Controlled Trials.
Lowe M; Bambhroliya Z; Patel H; Patel VJ; Vudugula SA; Cheruvu NP; Raza S; Okunlola OI
Cureus; 2023 Apr; 15(4):e38014. PubMed ID: 37223201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]